Insights

Building a Resilient GxP Compliance Program

In today’s complex life sciences landscape, a single quality failure—whether internal or at a supplier—can delay approvals, trigger inspections, or damage a brand. Robust internal and supplier audits are...

Strategic Regulatory Risk Planning for IND Submissions

An Investigational New Drug (IND) application is often the first major regulatory milestone for innovative therapies. Decisions made at this stage—about design, dose, endpoints, and CMC strategy—can significantly impact...